New mechanism of action for cilostazol: Interplay between adenosine and cilostazol in inhibiting platelet activation

Journal of Cardiovascular Pharmacology

Volumn 40, Issue 4, 2002, Pages 577-585

  Sun, Bing ^a   Le, Sang N ^a   Lin, Shihua ^a   Fong, Miranda ^a   Guertin, Maurice ^a   Liu, Yongge ^a   Tandon, Narendra N ^a   Yoshitake, Masuhiro ^a   Kambayashi, Jun ichi ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Adenosine; Aggregation; cAMP; Platelets; Uptake

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE DEAMINASE; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; COLLAGEN; CYCLIC AMP; MILRINONE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MECHANISM; ERYTHROCYTE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE; ANALYSIS OF VARIANCE; ANIMALS; CHO CELLS; CRICETINAE; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PLATELET ACTIVATION; TETRAZOLES;

EID: 0036786624     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200210000-00011     Document Type: Article

References (27)

1. Kimura Y, Tani T, Kanbe T, et al. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985;35:1144-9.
2. Tanaka T, Ishikawa T, Hagiwara M, et al. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor, on the contraction of vascular smooth muscle. Pharmacology 1988;36:313-20.
3. Ikeda Y. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor. Thromb Haemost 1999;82:435-8.
4. Cone J, Wang S, Tandon N, et al. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol 1999;34:497-504.
5. Liu Y, Fong M, Cone J, et al. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol 2000;36: 351-60.
6. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-9.
7. Burnstock G. Overview. In: Imai S, Nakazawa M, eds. Role of adenosine and adenine nucleotides in the biologic system. Amsterdam: Elsevier Science Publishers, 1991:3-16.
8. 3H]adenosine binding in relation to adenylate cyclase activity. Naunyn Schmiedebergs Arch Pharmacol 1984;325:226-33.
9. Agarwal KC, Buckley RS, Parks RE Jr. Role of plasma adenosine in the antiplatelet action of HL-725, a potent inhibitor of cAMP phosphodiesterase: species differences. Thromb Res 1987;47:191-200.
10. Dawicki DD, Agarwal KC, Parks RE Jr. Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor. Thromb Res 1986;43:161-75.
11. Azuma H, Takashima Y, Ishikawa M, et al. Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (oxagrelate), in human platelets in vitro. Jpn J Pharmacol 1984;34:159-70.
12. Anfossi G, Massucco P, Piretto V, et al. Interplay between milrinone and adenosine in the inhibition of human platelet response. Gen Pharmacol 1996;27:1149-54.
13. 2a selective adenosine receptor antagonist. Br J Pharmacol 1995;115:1096-102.
14. Suzuki K, Miura T, Miki T, et al. Infarct-size limitation by preconditioning is enhanced by dipyridamole administered before but not after preconditioning: evidence for the role of interstitial adenosine level during preconditioning as a primary determinant of cardioprotection. J Cardiovas Pharmacol 1998;31:1-9.
15. Glenn JR, Heptinstall S. Evidence that adenosine diphosphate can activate adenylate cyclase via conversion to adenosine in platelet-rich plasma containing magnesium. Thromb Haemost 1998;80:321-5.
16. 1 adenosine receptor, lowers the threshold for ischemic preconditioning in dogs. Circ Res 1996;79:415-23.
17. Agarwal KC. Modulation of platelet functions by plasma adenosine. In: Imai S, Nakazawa M, eds. Role of adenosine and adenine nucleotides in the biologic system. Amsterdam: Elsevier Science Publishers, 1991:273-88.
18. Agarwal KC, Zielinski BA, Maitra RS. Significance of plasma adenosine in the antiplatelet activity of forskolin: potentiation by dipyridamole and dilazep. Thromb Haemost 1989;61:106-10.
19. Igawa T, Tani T, Chijiwa T, et al. Potentiation of antiplatelet aggregating activity of cilostazol with vascular endothelial cells. Thromb Res 1990;57:617-23.
20. Marcus AJ, Broekman MJ, Drosopoulos JHF, et al. Thromboregulation by endothelial cells: significance for occlusive vascular diseases. Arterioscler Thromb Vasc Biol 2001;21:178-82.
21. Yegutkin G, Bodin P, Burnstock G. Effect of shear stress on the release of soluble ecto-enzymes ATPase and 5′nucleotidase along with endogenous ATP from vascular endothelial cells. Br J Pharmacol 2000;129:921-6.
22. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001;88:756-62.
23. Dawicki DD, Agarwal KC, Parks RE Jr. Adenosine metabolism in human whole blood: effects of nucleotide transport inhibitors and phosphate concentration. Biochem Pharmacol 1988;37:621-6.
24. Wawicki DD, Agarwal KC, Parks RE Jr. Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine. Biochem Pharmacol 1985;34:3965-72.
25. Mannarino E, Pasqualini L, Innocente S, et al. Physical training and antiplatelet treatment in stage II peripheral arterial occlusive disease: alone or combined? Angiology 1991;42:513-21.
26. Giansante C, Calabrese S, Fisicaro M, et al. Treatment of intermittent claudication with antiplatelet agents. J Int Med Res 1990;18:400-7.
27. Capecchi PL, Oasini FL, Cati G, et al. Experimental model of short-time exercise-induced preconditioning in POAD patients. Angiology 1997;48:469-80.